Australian psychedelic policy debate and TGA rescheduling of psilocybin and MDMA

Record summary

In 2023 Australia’s Therapeutic Goods Administration announced controlled access to psilocybin for treatment-resistant depression and MDMA for post-traumatic stress disorder through authorised psychiatrists. The decision is a major regional case for examining how altered-state therapies move from research into regulation, and how efficacy, risk, professional authority and public enthusiasm are negotiated. It does not establish broad benefits for recreational or spiritual use. Verification should distinguish the TGA decision, clinical evidence base, prescribing controls and subsequent implementation reports.